Premium
Clobetasol Propionate Cream Versus Halcinonide Cream in Psoriasis
Author(s) -
Ellis Charles N.,
Scott Eugene J.
Publication year - 1986
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1986.tb02261.x
Subject(s) - medicine , dermatology , veterans affairs , psoriasis , clobetasol propionate , administration (probate law) , family medicine , political science , law
C lobetasol propionate, probably the most potent topical corticosteroid yet developed,' has recently been approved for use in the United States. Confirming vasoconstrictor assay predictions of clinical effectiveness,^ clobetasol has been shown in doubleblind, multicenter trials '̂* to be statistically significantly superior in 0.05% cream formulation to 0.05% fluocinonide cream and in 0.05% ointment formulation to 0.05% betamethasone dipropionate in an optimized vehicle in the treatment of psoriasis. Clobetasol propionate cream 0.05% has also been compared with the potent topical corticosteroid cream haleinonide 0.1% in a recent two-center study. The results of the 2-week randomized double-blind, left-right paired trial (the most accurate comparative measure of topical corticosteroid efficacy in psoriasis) are presented below.